达格列净与美托拉宗在袢利尿剂抵抗心衰患者中的比较
多中心开放标签随机对照试验纳入61例因心衰住院且对静脉呋塞米抵抗的患者,比较达格列净10mg每日一次与美托拉宗5-10mg每日一次治疗3天的减充血效果。96小时体重下降达格列净组3.0kg、美托拉宗组3.6kg,差异无统计学意义;达格列净组呋塞米累积剂量更高但生化紊乱更轻。
要点
- 在袢利尿剂抵抗心衰患者中,达格列净减充血效果不优于美托拉宗
- 达格列净组呋塞米累积剂量更高但血钠血钾下降及尿素肌酐升高更少
- 两组肺部淤血和容量评估评分变化相似,严重不良事件相似
核心结论
- 在心衰伴袢利尿剂抵抗患者中,达格列净减轻淤血的效果不优于美托拉宗。
- 达格列净组呋塞米累积剂量更大但生化紊乱更轻。
研究设计与样本
- 多中心、开放标签、随机、活性对照试验,共随机61例因心衰住院且对静脉呋塞米治疗抵抗的患者。
- 患者随机接受达格列净10mg每日一次或美托拉宗5-10mg每日一次治疗3天,随访至第5天(96小时)。
- 主要终点为利尿效果,以体重变化(kg)评估。
主要发现
- 96小时体重平均下降达格列净组3.0(2.5)kg,美托拉宗组3.6(2.0)kg,平均差异0.65kg(95%CI -0.12,1.41;P=0.11)。
- 袢利尿剂效率达格列净组低于美托拉宗组,均值0.15(0.12)vs 0.25(0.19),差异-0.08kg(95%CI -0.17,0.01;P=0.10)。
- 96小时呋塞米累积剂量达格列净组977(492)mg,美托拉宗组704(428)mg。
- 肺部淤血和容量评估评分变化两组相似。
- 达格列净组血钠、血钾下降及尿素、肌酐升高幅度小于美托拉宗组,严重不良事件两组相似。
临床怎么用
- 对于心衰伴袢利尿剂抵抗的患者,达格列净不应被视为优于美托拉宗的减充血选择。
- 选用达格列净时需注意可能需要更大累积剂量的呋塞米,但生化紊乱可能更轻。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(61例),可能不足以检测组间差异。
- 治疗和随访时间较短(3天治疗,随访至96小时)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: To examine the decongestive effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin compared to the thiazide-like diuretic metolazone in patients hospitalized for heart failure and resistant to treatment with intravenous furosemide. METHODS AND RESULTS: A multi-centre, open-label, randomized, and active-comparator trial. Patients were randomized to dapagliflozin 10 mg once daily or metolazone 5-10 mg once daily for a 3-day treatment period, with follow-up for primary and secondary endpoints until day 5 (96 h). The primary endpoint was a diuretic effect, assessed by change in weight (kg). Secondary endpoints included a change in pulmonary congestion (lung ultrasound), loop diuretic efficiency (weight change per 40 mg of furosemide), and a volume assessment score. 61 patients were randomized. The mean (±standard deviation) cumulative dose of furosemide at 96 h was 977 (±492) mg in the dapagliflozin group and 704 (±428) mg in patients assigned to metolazone. The mean (±standard deviation) decrease in weight at 96 h was 3.0 (2.5) kg with dapagliflozin compared to 3.6 (2.0) kg with metolazone [mean difference 0.65, 95% confidence interval (CI) -0.12,1.41 kg; P = 0.11]. Loop diuretic efficiency was less with dapagliflozin than with metolazone [mean 0.15 (0.12) vs. 0.25 (0.19); difference -0.08, 95% CI -0.17,0.01 kg; P = 0.10]. Changes in pulmonary congestion and volume assessment score were similar between treatments. Decreases in plasma sodium and potassium and increases in urea and creatinine were smaller with dapagliflozin than with metolazone. Serious adverse events were similar between treatments. CONCLUSION: In patients with heart failure and loop diuretic resistance, dapagliflozin was not more effective at relieving congestion than metolazone. Patients assigned to dapagliflozin received a larger cumulative dose of furosemide but experienced less biochemical upset than those assigned to metolazone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04860011.
引用
- Yeoh, Osmanska, Petrie, et al. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J. 2023. PMID: 37210742. doi:10.1093/eurheartj/ehad341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。